For over 10 years, Selexis has built interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Our innovative technologies and world-class expert services significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. MAbs, growth factors, enzymes). From discovery to Phase II clinical trials, Selexis’ technology has been and is currently being used by more than 100 companies worldwide. Importantly, Selexis’ technology has been involved in production of biotherapeutics for a wide variety of indications and in the development of monoclonal antibody therapies for cancer (e.g. leukemia, breast and colon cancer, lymphoma) and auto-immune diseases (e.g. rheumatoid arthritis). With the recent launch of the Selexis SUREvariant screening™ platform, Selexis now enables customers to improve clinical success by identifying high quality lead candidates very early in the drug discovery process for the development of innovative treatments for patients.
For more information about partnerships, licensing, internal development capabilities, or other business development opportunities please contact Selexis.
